ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mRNA-1345 respiratory syncytial virus vaccine

Its studies are mostly in Virus Diseases · Coronavirus Infections · Influenza, Human, led by Moderna.

Drug pageMRNA-1345 respiratory syncytial virus vaccine: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 9, 202111 company-led studies, 1 open or runningNext primary completion: Aug 31, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Moderna111 open or runningphase 3since Nov 9, 2021Aug 20, 2020Aug 31, 2029phase 1 · NCT05743881

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 20, 2020First study: phase 1 study in Virus DiseasesFirst studyNCT04528719 · 651 enrolled · United States
  2. Nov 9, 2021Phase 3 study in Virus DiseasesNCT05127434 · 36,814 enrolled · United States, Argentina, Australia and more
  3. Apr 8, 2022Phase 3 study in Virus DiseasesNCT05330975 · 3,317 enrolled · United States
  4. May 25, 2022Phase 1 study in Coronavirus InfectionsNCT05397223 · 308 enrolled · United States
  5. Oct 14, 2022Phase 1 study in Influenza, HumanNCT05585632 · 392 enrolled · United States, Australia, United Kingdom
  6. Feb 15, 2023Phase 1 study in Respiratory Syncytial VirusNCT05743881 · 186 enrolled · United States, Panama, United Kingdom
  7. Sep 23, 20232 phase 3 studies in Virus DiseasesNCT06060457, NCT06067230
  8. Oct 18, 2023Phase 2 study in Virus DiseasesNCT06097299 · 349 enrolled · United States, Panama
  9. Nov 14, 2023Phase 2 study in Virus DiseasesNCT06143046 · 360 enrolled · United States, Canada, Chile and more
  10. Aug 5, 2025Phase 3 study in Virus DiseasesNCT07117487 · 507 enrolled · United States

Ahead

  1. Aug 31, 2029Primary completion: phase 1 study in Respiratory Syncytial VirusNCT05743881

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07117487Virus Diseases · United States3CompletedMar 27, 2026507
NCT06143046Virus Diseases · United States, Canada, Chile and more2CompletedMay 25, 2026360
NCT06097299Virus Diseases · United States, Panama2CompletedJun 27, 2025349
NCT06067230Virus Diseases · United States, Canada, Puerto Rico and more3CompletedJul 24, 20261,153
NCT06060457Virus Diseases · United States3CompletedJun 7, 20241,900
NCT05743881Respiratory Syncytial Virus · United States, Panama, United Kingdom1Active, not recruitingAug 31, 2029186
NCT05585632Influenza, Human · United States, Australia, United Kingdom1CompletedFeb 28, 2024392
NCT05397223Coronavirus Infections · United States1CompletedFeb 27, 2026308
NCT05330975Virus Diseases · United States3CompletedNov 8, 20243,317
NCT05127434Virus Diseases · United States, Argentina, Australia and more3CompletedJul 28, 202536,814
NCT04528719Virus Diseases · United States1CompletedJul 18, 2024651

How it is read

Names in the registry

  • “mRNA-1345”, 11 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.